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ABSTRACT         ARTICLE INFO______________________________________________________________     ______________________
Validate the EORTC risk tables in Brazilian patients with NMIBC.
Methods: 205 patients were analyzed. The 6 parameters analyzed were: histologic 
grading, pathologic stage, size and number of tumors, previous recurrence rate and 
concomitant CIS. The time for first recurrence (TFR), risk score and probability of re-
currence were calculated and compared to the probabilities obtained from EORTC risk 
tables. C-index was calculated and accuracy of EORTC tables was analyzed. Results: 
pTa was presented in 91 (44.4%) patients and pT1 in 114 (55.6%). Ninety-seven (47.3%) 
patients had solitary tumor, and 108 (52.7%) multiple tumors. One hundred and three 
(50.2%) patients had tumors smaller than 3 cm and 102 (40.8%) had bigger than 3 cm. 
Concomitant CIS was observed in 21 (10.2%) patients. Low grade was presented in 95 
(46.3%) patients, and high grade in 110 (53.7%). Intravesical therapy was utilized in 
105 (56.1%) patients. Recurrence was observed in 117 (57.1%) patients and the mean 
TFR was 14,2 ± 7,3 months. C-index was 0,72 for 1 year and 0,7 for 5 years. The re-
currence risk was 28,8% in 1 year and 57,1% in 5 years, independently of the scoring 
risk. In our population, the EORTC risk tables overestimated the risk of recurrence in 1 
year and underestimated in 5 years.
Conclusion: The validation of the EORTC risk tables in Brazilian patients with NMIBC 
was satisfactory and should be stimulated to predict recurrence, although these may 
overestimated the risk of recurrence in 1 year and underestimated in 5 years.
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INTRODUCTION
At least 85% of patients with bladder can-
cer (BCa) present the disease confined to the mu-
cosa (Ta and Tis) or submucosa (T1), representing 
non-muscle invasive bladder cancer (NMIBC). 
These are heterogeneous tumors with high varia-
tion of reported recurrence rates in literature. They 
vary from 15-61% at first year to 31-78% at five 
years (1, 2). Stratification is responsible for the 
correct choice of treatment, based on recurrence 
and progression risks (3).
European Organization for Research and 
Treatment of Cancer (EORTC) has published a 
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score system based on the risks of progression and 
recurrence of patients with NMIBC following TRUS 
(4). Recently, the European Association of Urology 
(EAU) has adopted in its guidelines the risk tables 
and recommends stratification of NMIBC with 
low, intermediate and high risk of recurrence (5). 
However, external validations are necessary to 
adopt these risk tables in clinical practice and in 
different populations (6-9).
Although score EORTC risks are widely used 
in daily urological practice, there are not enough 
data from South America, particularly from Brazil, 
to apply them in the Brazilian population.
MATERIAL AND METHODS
Prospectively and consecutively, 205 pa-
tients with NMIBC stages Ta and T1 submitted to 
bladder TRUS resection, from January 2003 to Oc-
tober 2010 were analyzed. Patients were treated 
at the Department of Uro-oncology of Instituto 
Catarinense de Urologia in Itajaí, Santa Catarina, 
Brazil. The patients were attended by the public 
health service and private practice and had all 
socio-economic status. Ethnic background was 
not considered, since it is virtually impossible to 
distinguish these characteristics in this widely ge-
netic and ethnic variant population.
New and recurrent cases were considered. 
It was excluded patients submitted to previous ra-
diotherapy and chemotherapy due to other tumors 
throughout the period of study, patients with in-
complete data or follow-up, who missed clinical 
and laboratory follow-up, and those who refused 
to participate in the study and failed to sign the 
Consent Form. These excluded patients were not 
considered for evaluation. Data collection was 
performed by one author and histologic exam by 
two pathologists, in order to minimize interpreta-
tion variability among observers. Pathologic exam 
was performed in a non-blind manner, that is, the 
pathologists had access to all clinical and labora-
tory data. The study was approved by the Ethical 
Committee of the Universidade do Vale do Itajaí.
Use of intravesical therapy (IVT) was de-
termined previously to inclusion and during 
follow-up: none IVT, use of intravesical mitomi-
cin C, intravesical immunotherapy with BCG and 
combined mitomicin C and BCG IVT. Mitomicin C 
administration was performed in the post-surgical 
period after up to 12 hours of TURS. BCG was ad-
ministered using induction protocol (once a week 
during 6 weeks after 2 to 4 weeks of TURS) and 
maintenance protocol (one series of three weekly 
cycles of IVT during 6 weeks repeated at 3, 6, 12, 
18, 24, 30 and 36 months after induction proto-
col). A second bladder TRUS was performed 2 to 
6 weeks after the initial TURS and always when 
it was detected incomplete initial resection or ab-
sence of muscle, T1 and/or high grade except pri-
mary CIS, according to EAU guidelines (5).
Follow-up included urological consulta-
tion, urethrocistoscopy, urinary cytology and ima-
ge exams. It was performed every 3 months in the 
first 2 years, every 6 months in the next 3 years, 
and annually until the end of the study and/or 
one of the end-points. Recurrence was defined as 
a new lesion after the treatment of the primary tu-
mor diagnosed by cystoscopy and/or image exam 
and confirmed by histopathology.
The six parameters described by EORTC 
study (4) were analyzed: histologic grade, pT stage 
(TNM 2009), size and number of tumors, presence 
of in situ carcinoma (CIS) and previous recurrence 
rate. Risk scores (Table-1) and recurrence probabi-
lity in 1 and 5 years and time to first recurrence 
(TFR) were estimated in order to compare them 
with the data of the study by Silvester et al. (4) 
and accuracy analysis. Patients were divided in 4 
risk groups according to their scores (Table-2) and 
it was determined the number of patients in risk of 
TFR in 1 and 5 years.
Five end-points were analyzed for the end 
of the study: free of disease, death, death due to 
disease, noncompliance with treatment, and dise-
ase progression.
Statistical analysis
SPSS software (version 17, SPSS, Chicago 
Illinois) was used. For statistical validation, recur-
rence rates at 1 and 5 years were determined. TFR 
was estimated by Kaplan-Meier method. Valida-
tion method included discrimination by accordan-
ce index (C index), representing the probability of 
accordance between predicted value (EORTC) and 
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observed (10). When C is equal to 0.5, there is no 
discrimination (random distribution) or when it is 
1, there is discrimination with perfect accordance 
(11). An adequate C index was assumed when it was 
equal or higher than the one of Sylvester et al. study 
(4). Accuracy was determined by calibration betwe-
en recurrence probabilities in 1 and 5 years obtai-
ned by the present study and by Silvester et al. (4).
RESULTS
Table-3 shows patients characteristics and 
comparison with Siylvester et al. data (4).
Tumor recurrence was observed in 117 
(57.1%) patients. 137 (66.5%) presented primary 
tumor and 68 (33.2%) previous recurrent tumors, 
among which 35 (17.1%) with less than 1 recur-
rence per year and 33 (16.1%) with more than 1 
recurrence per year. TFR medium was 14.2±mon-
ths, minimum 3 and maximum 36 months. Re-
currence in 1 year was identified in 59 (28.8%) 
patients and in 5 years in all 117 (571%) patients. 
Figures 1 and 2 show TFR in 1 and 5 years, respec-
tively, stratified according to risk score groups of 
EORTC and show the number of patients at risk in 
each interval of 3 months, when TFR was evalu-
ated in 1 year, and every 12 months, when it was 
evaluated in 5 years.
Calculated C index for tumor recurrence was 
0.72 for 1 year and 0.7 for 5 years, superior to 0.66 
described by Sylvester et al. (4) for the same periods.
Risk of recurrence was 28.8% in 1 year and 
57.1% in 5 years, regardless the score. Comparison 
of probabilities of recurrence in 1 and 5 years with 
Sylvester et al. results (4) in each group of risk 
score is shown in Table-4. Probability of recur-
rence in 1 year was lower in all risk groups than 
those described by Sylvester et al. (4). In 5 years, 
risk was superior, except in risk group score zero. 
For this sample, EORTC Tables overestimated the 
risk of recurrence in 1 year and underestimated 
in 5 years, except when score was zero, but the 
confidence interval overlapped.
Table 1 - Recurrence predictors for risk score calculus.
Factor Recurrence
Number of tumors
Single 0
2 to 7 3
>or=8 6
Tumor diameter
<3.0cm 0
>or=3.0cm 3
Primary previous recurrence
<or=1 recurrence/year 2
>1 recurrence/year 4
Cathegory
pTa 0
pT1 1
Concomitant CIS
No 0
Yes 1
Histologic grade (OMS 1973) 
G1 0
G2 1
G3 2
Total score 0-17
Source - Babjuk M et al., 2013
Table 2 - Score system for NMIBC risk of recurrence calculus.
Recurrence score Recurrence probability in 1 year Recurrence probability in 5 years Recurrent risk group
% (95% 1A) % (95% 1A)
0 15 (10-19) 31 (24-37) Low risk
1-4 24 (21-26) 46 (42-49) Intermediate risk
5-9 38 (35-41) 62 (58-65) Intermediate risk
10-17 61 (55-67) 78 (73-84) High risk
Source - Babjuk M et al., 2013
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Table 3 - Sample characteristic of the present study and of EORTC series.
Characteriscs Our population n (%) EORTC n (%)
Total number of patients 205 2596
Age (years)
≤60 55 (26.8) 859 (33.1)
61-70 86 (42) 890 (34.3)
71-80 55 (26.8) 690 (26.6)
>80 9 (4.4) 118 (4.5)
unknown 0 39 (1.5)
Gender
male 144 (70.2) 2044 (78.7)
female 61 (29.8) 515 (19.8)
unknown 37 (1.4)
T stage
pTa 91 (44.4) 1451 (55.9)
pT1 114 (55.6) 1108 (42.7)
Number of tumors
Single 97 (47.3) 1465 (56.4)
2 to 5 64 (31.2) 836 (32.2)
>5 44 (21.5) 255 (9.8)
unknown - 45 (1.7)
Tumor size
<3cm 103 (50.2) 2087 (80.4)
≥3cm 102 (49.8) 464 (17.9)
unknown 0 45 (1.7)
CIS presence
Yes 21 (10.2) 113 (4.4)
No 184 (89.8) 2440 (94.0)
Recurrence
Primary 137 (66.8) 1405 (54.1)
≤1/year 35 (17.1) 505 (19.5)
>1/year 33 (16.1) 645 (24.8)
Histologic grade
Low grade(G1/G2) 95 (46.3) 2260 (87.1)
High grade (G3) 110 (53.7) 271 (10.4)
Intravesical therapy
None 90 (43.9) 561 (21.6)
Chemotherapy 24 (11.7) 2035 (78.4)
BCG 46 (22.4) -
Chemotherapy + BCG 45 (22) 361 (13.9)
Follow-up (months)
Medium 63.6 46.8
Minimum 6 -
Maximum 144 177.6
Recurrence
Yes 117 (57.1) 1240 (47.8)
No 88 (42.9) 1356 (52.2)
End-point
Free of disease 127 (62) 1743 (67.1)
Progression 25 (12.2) 279 (10.7)
Death by disease 21 (10.2) 262 (10.1)
Death 15 (7.3) 461 (17.8)
Noncompliance with treatment 17 (8.3) 130 (5)
Survival
Alive 152 (74.2) 1743 (67.1)
Dead 36 (17.5) 279 (32.9)
Unknown 17 (8.3) -
ibju | ExtErnal Validation of EortEC risk tablEs to PrEdiCt rECurrEnCE in brazilian PatiEnts with nMibC
936
Score Number of patients at risk in the beginning of each interval
0 30 30 30 29 25
1-4 54 54 54 52 47
5-9 78 78 74 69 59
10-17 43 43 38 27 17
Table shows the number of patients at risk in every interval of 3 months.
Figure 1 - Time to first recurrence in 1 year according to 
EORTC score in this series.
Score Number of patients at risk in the beginning of each interval
0 30 25 23 22 21 18
1-4 54 47 33 18 18 18
5-9 78 59 32 21 12 11
10-17 43 17 5 4 3 3
Table with the number of patients at risk at intervals of 12 months.
Figure 2 - Time to first recurrence in 5 years according to 
eortc score in this series.
Table 4 - Comparision of recurrence probabilities according to risk score of EORTC and of this study in 1 and 5 years
Recurrence score number of 
patients*
Probability of recurrence in 1 year (IC 95%) Probability of recurrence in 5 years (IC 95%)
EORTC Present study EORTC Present study
0 30 15 (10 - 19) 6.7 (0.8 - 22.1) 31 (24 - 37) 10.0 (2.1 - 26.5)
1 - 4 54 24 (21 - 26) 14.8 (6.6 - 27.1) 46 (42 - 49) 46.3 (32.6 - 60.4)
5 - 9 78 38 (35 - 41) 29.5 (19.7 - 40.9) 62 (58 - 65) 66.7 (55.1 - 76.9)
10 - 17 43 61 (55 - 67) 60.5 (44.4 - 75.0) 78 (73 - 84) 86.0 (72.1 - 94.7)
205 28.8 (22.7 - 35.5) 57.1 (50.0 - 63.9)
*number of patients in the presente study in each risk group of EORTC
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DISCUSSION
BC has a higher incidence in men, 3 to 4 
times higher than in women. Median age of pa-
tients with BC is 70 years (12). Sylvester et al. (4) 
identified a relationship of men/women of 3.96 
with 80% of male patients and median age of 65 
years. We observed a 2.3/1 proportion of men/wo-
men with 70.2% of male patients and a median 
age of 66.61 years. This observed difference may 
have occurred to the increasing smoking habitus 
and higher search for preventive medical attention 
of women observed in daily practice.
Our sample showed higher tumor potential 
aggressiveness and of high risk than literature (1, 
3) and Sylvester et al. study (4) due to a higher 
proportion of patients stage T1 than literature (1, 
3) (5.6% versus 20%) and of high grade tumors 
(53.7 versus 10.7%), multiple (52.7% versus 42%), 
larger than 3cm (49.8% versus 17.9%) and with 
CIS (10.2% versus 4.4%) than Sylverster et al. stu-
dy (4). Also, the reduced number of CIS cases in 
Sylvester et al. (4) study lead to low accuracy of 
EORTC risk tables to predict recurrence and pro-
gression of these patients (3). However, the present 
study observed the same proportion of CIS descri-
bed in literature (1, 3, 5) expressing a population 
close to reality.
Pillai et al. (9) described some limitations 
of Sylvester et al. study (4): collection of data by a 
single researcher and pathologic exam by a single 
pathologist may minimize interpretation variabi-
lity among observers. The present study has not 
shown significant variability among observers, re-
ducing the possibility of bias of interpretation and 
analysis of data.
Sylvester et al. (4) based their study in 7 
clinical trials, that used several IVT for adjuvant 
treatment following TURS. In their sample, 78.4% 
of patients received IVT, a number significantly 
higher when compared to present study and to 
the actual need on clinical daily practice. Intra-
vesical chemotherapy protocols used by Sylvester 
et al. (4) were old and the use of instillation of 
chemotherapy drug right after surgery, protocol of 
induction and maintenance of adjuvant intravesi-
cal BCG and re-TURS were not considered for the 
development of EORTC risk Tables. In our sample, 
43.9% of patients did not receive any adjuvant 
IVT. In the other 56.1% patients, 11.7% received 
chemotherapy using mitomicin C, 22.45 BCG and 
22% a combination of Mitomicin C and BCG. The 
high use of intravesical chemotherapy and the old 
protocols used by Sylvester t al. (4), the impro-
vement of chemotherapy administration and the 
increased adjuvant use of BCG nowadays may re-
duce the predictive power of the EORTC Tables.
Although submitted to adequate treatment, 
up to 70% of patients with Ta and T1 tumors will 
present recurrence in 1 year following TURS as 
single treatment (1, 13). Sylvester et al. (4) repor-
ted 47.8% of recurrence in a 14-year follow-up 
and 44.3% with at least one recurrence when ad-
mitted to study. Among these, recurrence occur-
red at least once a year in 19.5% and more than 
once a year in 24.8%. Our results are slightly close 
to those reported in literature (1, 3, 5) than those 
of Sylvester et al. (4). Recurrence rate was 57.1% 
in the 12-year follow-up. Also, 33.2% of patients 
had already presented previous recurrence prior 
to admittance to study. Among these, 17.1% with 
less than one recurrence per year and 16.1% with 
more than one recurrence per year. The lowest 
recurrence observed by Sylvester et al. (4) when 
compared to literature (1, 3, 5) and to this study 
may be explained by the significant difference of 
patients that received IVT (78.4% versus 56.1%). 
This fact may have been caused by a selection bias 
of Sylvester et al. study (4), that included patients 
from clinical studies proposed to analyze pro-
phylactic value of IVT following TURS and not 
the study of prognostic factors of recurrence and 
progression. A vicious sample was selected, since 
almost 80% of patients received IVT.
In a medium follow-up of 5.5 years with 
maximum 12 years, among 117 patients that pre-
sented recurrence, TFR was 14.2±7.3 months, mi-
nimum 3 months, maximum 36 months. Recur-
rence in 1 year was verified in 28.8% and in 100% 
in 5 years, while in Sylvester et al. study (4) TFR 
was 31 months. It was observed more than 50% 
lower TFR in the studied population. But the time 
graphic of stratified recurrence of risk groups pre-
sented a similar behavior of that of Sylvester et al. 
(4), mainly at 5 years. In our patients, recurren-
ce was observed in a significant earlier time that 
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could be explained by the lack of use of intravesi-
cal chemotherapy and due to tumor characteristics 
previously described.
Evaluated end-points were similar to tho-
se of Sylvester et al. (4) except for death, with a 
significant difference in this study (32.9% versus 
7.3%). Their study showed a higher proportion of 
men, with a usually lower life expectancy that can 
explain this difference between studies. Follow-up 
was similar to Sylvester et al. (4), although lower 
in total (144 versus 177.6 months) but with a me-
dium higher time (66 versus 46.8 months).
Our C index was 0.72 for recurrence in 1 
year and 0.7 for 5 years, superior to 0.66 described 
by Sylvester et al. (4) for both periods. When C 
indexes are compared, we conclude that there was 
discrimination or accordance between them. Also, 
our C-index showed a better performance than 
those of Sylvester et al. (4) showing a better accor-
dance of our results to clinical reality. This aspect 
allows this study to be applied in daily practice.
In relation to accuracy, risk tables overes-
timated the recurrence risk in 1 year and underes-
timated in 5 years, probably due to the low use of 
BCG and high use of intravesical chemotherapy 
with old protocols utilized by the Sylvester et al. 
study (4), the use of immediate intravesical che-
motherapy with more modern drugs, more ade-
quate use of BCG and routine use of re-TURS in 
the high risk groups of our study.
In a recent systematic review, Kluth et al. 
(14) pointed out the importance of treatment im-
pact on end-points of the predictive models and 
the need of external validations before incorpora-
tion in daily practice. External validations of EOR-
TC tables are shown in Table-5.
Fernandez-Gomez et al. (8) performed ex-
ternal validation of EORTC risk Tables in patients 
treated with intravesical BCG, although overes-
timated the recurrence risk. Ding et al. (15) and 
Hernandez et al. (16) validated the EORTC model, 
since the confidence intervals of recurrence ra-
tes matched those of Sylvester et al. (4). Xu et al. 
(17) also validated the model in patients treated 
with intravesical epirrubicin, although the score 
overestimated the recurrence rate. Seo et al. (18) 
validated the risk Tables, since identified a recur-
rence rate similar to Sylvester et al. (4). Ajili et al. 
(19) and Ather and Zaidi (20) identified significant 
correlation for recurrence in 1 year with the Syl-
vester et al. study (4). Altieri et al. (21) identified 
a recurrence rate similar to those of EORTC Tables 
and confirmed their use essential to daily practice. 
Van Rijin et al. (22) validated the EORTC Tables 
with a multicenter study treating patients with 
primary NMIBC and they also advocated their use 
in that population.
Pillai et al. (9) showed a significant diffe-
rence of recurrence probabilities between their stu-
dy and that of Sylvester et al. (4). An inadequate 
number of patients did not allow a conclusion for 
external validation. Xylinas et al. (23) analyzed 
the discrimination of the EORTC Tables and the 
CUETO score system and identified that both mo-
dels overestimated the recurrence risk of patients 
with high risk, but their study was retrospective 
and multicenter. Sakano et al. (24) affirmed that 
the EORTC model could not be used in Japanese 
patients. Borkowska et al. (25) pointed out that 
risk scores of EORTC overestimated the recurrence 
risk but, similar to Sylvester et al. (4) study, their 
sample did not use modern intravesical protocols, 
what could have limited their results.
Our study presents several limitations. 
Although our population was homogeneous and 
close to clinical reality, the size was significan-
tly smaller than the original EORTC study (4). 
However, the inclusion of 205 patients was satis-
factory after comparison with already published 
validations; the design study and long follow-up 
allow us to trust in our results. However, although 
we had a rigorous control of data inclusion and 
follow-up, sometimes clinical follow-up is diffi-
cult in Brazil. It is common difficulties to re-TURS 
following 3 months, as recommended, delayed 
control cystoscopies, delayed ambulatory consul-
tation, and lack of comprehension of the actual 
severity of the disease by the patients.
The greatest difficulty we observed for 
external validation was the significant disparity 
between samples of our study and that of EOR-
TC. Sylvester et al. study (4) was not proposed to 
create prognostic Tables, as previously described, 
while our study was proposed to analyze those Ta-
bles in a more real population. The great merit of 
Sylvester et al. study (4) was the development of 
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Table 5 - Comparision of external validation studies of risk tables of EORTC.
Number of 
patients
Sample 
studied
Studied variables Endpoints Accuracy 
calibration
C-index External 
validation
Fernandez-Gomez et 
al. (8)
1062 Spain Number of tumors, 
size, previous 
recurrence rate, T 
stage, tumor grade, 
concurrent CIS
RR 1 and 5 years 
stratified according 
to risk groups
Overestimated RR 0,63 for 
1 and 5 
anos
YES
Pillai et al. (9) 109 United 
Kingdom
=
RR 1 and 5 years 
stratified according 
to risk groups
Underestimated 
RR in all risk 
groups
0,62 for 1 
year
0,63 for 5 
years
NO
Xylinas et al. (23) 4689 Spain
=
RR in 57 months Overestimated RR 
mainly in high risk 
patients
0.597 NO
Ding et al. (15) 301 China - RP in 1 and 5 years Overlapped CI NR YES
Sakano et al. (24) 592 Japan
-
recurrence-free 
survival
NR NR NO
Borkowska et al. (25) 91 Poland
=
RR in 1 year 
stratified according 
to risk groups
Overestimated RR NR NO
Xu et al. (17) 389 Taiwan
-
RR 1 and 5 years 
stratified according 
to risk groups
Overestimated RR NR YES
Seo et al. (18) 251 South 
Korea =
RR 1 and 5 years 
stratified according 
to risk groups
Overestimated RR NR YES
Ather and Zaidi (20) 92 Pakistan
=
RR in 1 year Underestimated 
RR
NR YES
Altieri et al. (21) 259 Italy
=
RR in 1, 3 qnd 5 
years
Overestimated 
RR in high and 
intermediate risk 
groups
NR YES
Ajili et al. (19) 112 Tunis
=
RR in 1 year 
stratified according 
to risk groups
Overestimated RR 
except in high risk 
patients
NR YES
Hernández et al. (16) 417 Spain
=
RR 1 and 5 years 
stratified according 
to risk groups
Overlapped CI NR YES
Lammers et al. (26) 728 Holand - RP in 1 and 5 years Overlapped ci NR YES
van Rijin et al. (22) 230 Multicenter
=
RR 1 and 5 years 
stratified according 
to risk groups
- NR YES
Almeida et al. 205 Brazil
=
RR 1 and 5 years 
stratified according 
to risk groups
0,72 for 1 
year
0,7 for 5 
years
YES
RR = Recurrence rate; RRI = recurrence risk; RP = Recurrence Probability; IC = confidence interval; NR = no reported = number of tumors, size of tumors, previous recurrence rate, T stage, tumor 
grade, concomitant CIS
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the idea to stablish a mechanism to calculate the 
recurrence risk of patients with NMIBC. However, 
EORTC Tables must be adapted in order to become 
more reliable and used in daily urological practice.
CONCLUSIONS
The already accepted use of the EORCT 
model requires some reflections. There is a need 
to improve risk tables of recurrence in order to 
minimize distinct ethnic, geographic and clini-
cal practice differences around the World. Tu-
mor markers and genetic mapping are necessary 
to identify more precisely the biologic behavior 
of those tumors.
Although EORTC risk Tables overestimated 
the recurrence risk of tumor in 1 year and unde-
restimated in 5 years, their external validation in 
patients with NMIBC in the south region of Brazil 
was adequate and their use to predict recurrence 
must be reinforced.
ABBREVIATIONS
BC = bladder cancer
CIS = carcinoma in situ
EORTC = European Organization for Research and 
Treatment of Cancer
EAU = European Association of Urology
IVT = intravesical treatment
NMIBC = Non-muscle invasive bladder cancer
TURS = Transurethral resection
TFR = Time to first recurrence
CUETO = Club Urológico Español de Tratamiento 
Oncológico
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